A Medline search of the English-language literature published between 1975 and May 1999 was performed. 'Breast', 'biopsy needle', 'diagnosis', 'non(-)palpable' (all subheadings) were used as keywords. A cross-reference search completed the exploration. Because the aim of this study was to assess the diagnostic accuracy of large-core needle biopsy, publications addressing fine-needle aspiration were not eligible for inclusion in the metaanalysis.
Publications were included in the meta-analysis if the pre-set inclusion criteria were met: (1) the mammographic lesions had to be non-palpable; (2) all histological diagnoses of large-core needle biopsy specimens had to be confirmed by either surgical biopsy or adequate follow-up (defined as a minimum of 2 years in at least 90% of the patients); (3) the absolute number of benign and malignant diagnoses had to be derivable; (4) a minimum of five largecore needle biopsy specimens per non-palpable lesion had to be obtained (as has been advocated by Liberman et al (1994) ). A total of 118 papers, addressing the issue of large-core needle biopsy for non-palpable breast disease was retrieved. Twenty-five publications were comments, letters or review articles and in 50 studies, Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: a meta-analysis
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the diagnostic performance of large-core needle biopsy was not the object of study. Of the 43 publications addressing the diagnostic accuracy of large-core needle biopsy, five publications were included in the meta-analysis (Parker et al, 1991; Elvecrog et al, 1993; Gisvold et al, 1994; Pijnappel et al, 1997; Jackman et al, 1999) . (A list of the 38 excluded publications and the reasons for exclusion is available upon request.) Thirty studies were excluded because the histological diagnoses on needle biopsy were not satisfactorily confirmed. Six studies were excluded because an average of fewer than five core biopsies per lesion was obtained. In one paper, the absolute number of non-palpable lesions was not derivable and one paper was excluded because the absolute number of benign and malignant lesions was not derivable. Two of the authors (HMV and VCMK) independently extracted the data from the studies using a standard form. In case of discrepancies consensus was reached.
Meta-analysis of diagnostic accuracy
The diagnostic accuracy of large-core needle biopsy was assessed using a method introduced by Burbank and Parker (1998) . For this purpose, the results of the studies were collapsed into a four by four table. Firstly, the histological outcomes from the needle biopsy procedures were classified according to one of the following four categories:
1. benign breast disease (including normal breast tissue) 2. atypical ductal hyperplasia (ADH) (This category also includes other high-risk lesions, e.g. lobular carcinoma in situ, atypical lobular hyperplasia and radial scar. Because ADH is the most common of these lesions, this category was named accordingly 3. ductal carcinoma in situ (DCIS) 4. infiltrating breast cancer.
Lesions that were surgically removed were divided into the same four categories according to the histological diagnosis. Lesions with a benign histological large-core needle biopsy result that were not surgically removed and that remained unchanged during follow-up, were categorized as benign.
Then, the cells in the four by four The underestimate cells were divided into three subcategories. The DCIS underestimate rate was defined as the percentage of DCIS lesions on large-core needle biopsy that is upgraded to invasive cancer in the surgical specimen.
The ADH underestimate rate was defined as the percentage of ADH lesions on large-core needle biopsy that is upgraded to DCIS or invasive cancer. The reason that these outcomes were classified as underestimates rather than misses is that a diagnosis of ADH on large-core needle biopsy is always an indication for surgical biopsy. Atypical ductal hyperplasia is a benign disease known to be associated with an increased risk of breast cancer (Marshall et al, 1997; Page et al, 1998; Tavassoli, 1998) . Several studies have already demonstrated that when ADH is diagnosed on large-core needle biopsy, the risk of malignancy at surgical biopsy is 33-52% (Liberman et al, 1995; Gadzala et al, 1997; Moore et al, 1997; Fuhrman et al, 1998) . Similarly, histological diagnoses of radial scar, lobular carcinoma in situ and atypical lobular hyperplasia on large-core needle biopsy are often associated with invasive or in situ carcinomas (Lee et al, 1997; Liberman et al, 1997; Brown et al, 1998; Fuhrman et al, 1998) , and therefore always an indication for surgical biopsy.
The miss rate was defined as the proportion of all breast cancers (invasive cancer and DCIS) with a diagnosis of only benign disease on large-core needle biopsy. Accordingly, the sensitivity rate was defined as one minus the miss rate.
The remaining overestimate and underestimate cells were then reclassified into clinically relevant categories (Table 1) . For clinically relevant purposes, a diagnosis of benign disease on largecore needle biopsy, upgraded to ADH, was reclassified as agreement. Although the finding of ADH in a surgical specimen is associated with an increased risk of breast cancer (Marshall et al, 1997; Page et al, 1998; Tavassoli, 1998) , it does not have clinical consequences. Moreover, ADH lesions are by definition small (≤2 mm) (Tavassoli, 1998) and therefore the finding of ADH in a surgical specimen is nearly always incidental. In addition, Burbank and Parker (1998) argue that overestimates are actually clinically relevant agreements rather than disagreements. For example, if large-core needle biopsy had identified invasive breast cancer and the surgical specimen contained only fibrocystic changes, the target lesion would still maintain the diagnosis of invasive cancer. The lower degree of pathology seen in the open Table 1 Classification of large-core needle biopsy results as agreements (A), underestimates (U) and overestimates (O) and reclassification for clinical relevance in brackets (adapted from Burbank and Parker, 1998) Large-core needle biopsy Open biopsy/follow-up
ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ.
biopsy specimen can be explained by either complete removal of the lesion by the large-core needle biopsy (Dronkers, 1992; Mikhail et al, 1994) or by inadequate surgical excision (lesion not removed). Therefore, these overestimate cells were also reclassified as agreement cells. Accordingly, the reclassified agreement rate was defined as the proportion of cells not classified as DCIS underestimate, ADH underestimate or miss. Underestimate rates, miss rates and reclassified agreement rates were calculated as described above for each of the five studies as well as pooled estimates after testing for homogeneity of the studies using Fisher exact test (Altman, 1991) .
Finally, the clinical consequences of the miss rate of the largecore needle biopsy technique were evaluated for different disease prevalences. For this purpose, the predictive value of a benign biopsy result was calculated for different disease prevalences, applying the following formula:
Risk of malignancy despite benign histological diagnosis on large-core needle biopsy = (1Ϫsensitivity)*prevalence/((1Ϫsensitivity)*prevalence + specificity*(1Ϫprevalence))
As discussed previously, a malignant diagnosis on large-core needle biopsy followed by a benign diagnosis of the open biopsy specimen was not considered as an overestimate or false-positive result. We therefore agreed on a specificity rate of the large-core needle biopsy of 1.0. Statistics were performed using Statistical Package for Social Sciences 6.0 (SPSS Inc. Chicago, IL, USA). Exact confidence intervals were calculated. Table 2 shows the data obtained from the five papers. In all studies, stereotactic guidance was applied. Pijnappel et al (1997) used ultrasound guidance in addition to stereotactic guidance in three cases (4%). Stereotactic biopsy was performed with the patient in prone position by using a 14-gauge needle and a long throw biopsy gun. In four studies all histological diagnoses of large-core needle biopsy specimens were confirmed by additional open biopsy and generally these two procedures took place on the same day (Parker et al, 1991; Elvecrog et al, 1993; Gisvold et al, 1994; Pijnappel et al, 1997) . In the study of Jackman et al (1999) , 295 patients (61%) with a benign diagnosis on large-core needle biopsy did not undergo immediate open biopsy, but mammographic follow-up. During follow-up, repeat biopsy was performed in 36 patients. Of the remaining 259 patients, 96% was followed for at least 2 years and the median follow-up period was 55 months. Lesions with discrepancy between mammography and histological diagnosis on large-core needle biopsy were surgically removed. Also, patients with a diagnosis of atypical ductal or lobular hyperplasia, radial scar or carcinoma (invasive and in situ) on large-core needle biopsy were planned for surgery.
RESULTS
A total of 865 large-core needle biopsy procedures was performed and 56% was carried out in the context of one study (Jackman et al, 1999) . In four studies the percentage of lesions with microcalcifications was reported (Elvecrog et al, 1993; Gisvold et al, 1994; Pijnappel et al, 1997; Jackman et al, 1999) which varied from 21 to 48%. The malignancy rate varied from 23 to 57% and four studies reported that 9-40% of all malignant All studies were conducted in the USA, except for the study of Pijnappel et al, which was conducted in The Netherlands. lesions was DCIS only. The number of complications was low; only one haematoma and one infection (which also might have been caused by the open biopsy procedure) were described. Table 3 presents the DCIS and ADH underestimate rates. The DCIS underestimate rate was derivable for three of five studies and the pooled DCIS underestimate rate of these three studies was 15% (95% CI 8-26%). The ADH underestimate rate could be derived for four studies and the pooled ADH underestimate rate was 40% (95% CI 26-56%).
In Table 4 the sensitivity rate of large-core needle biopsy for all studies was calculated. Of 307 carcinomas, eight were diagnosed as benign by large-core needle biopsy (3%). Consequently, the sensitivity rate was 97% (95% CI 95-99%).
The reclassified agreement rate was derivable for two studies. In the study of Pijnappel et al (1997) , there was clinically relevant discrepancy in five of 76 cases (one ADH underestimate, three DCIS underestimates and one miss), resulting in a reclassified agreement rate of 93% (95% CI 85-98%). In the study of Jackman et al (1999) there were 26 discrepancies (16 ADH underestimates, eight DCIS underestimates and two misses) on a total of 483 lesions, resulting in a reclassified agreement rate of 95% (95% CI 92-97) in this study. Combining the results of these two studies gives rise to a pooled reclassified agreement rate of 94% (95% CI 92-96%). Table 5 shows the risk of malignancy despite benign large-core needle biopsy result for different assumptions of breast cancer prevalences. In a population with a low prevalence of malignancy of e.g. 20% (i.e. USA), the probability of a carcinoma being present despite benign needle biopsy result is low (0.6%). In Western Europe, however, 60-70% of the lesions detected by screening and referred for histological biopsy turn out to be malignant, due to the use of different cut-off points for referral. If in such a setting a large-core needle biopsy reveals benign disease, the probability of a carcinoma being present will still be 4-6%.
DISCUSSION
This meta-analysis showed that the diagnostic accuracy of largecore needle biopsy is high. The sensitivity rate was 97% and the reclassified agreement rate was 94%. Accordingly, large-core needle biopsy seems to be an attractive alternative for the needlelocalized open breast biopsy.
We used the approach of Burbank and Parker (1998) for evaluating the diagnostic performance of large-core needle biopsy. With this approach, the reclassified agreement rate is not an estimate for exact histological accordance between large-core needle biopsy and surgical biopsy. Certain discrepancies between large-core needle biopsy and open biopsy (e.g. fibrocystic disease on largecore needle biopsy and ADH on surgical biopsy, or DCIS on largecore needle biopsy and fibrocystic disease on open biopsy) were considered as agreements. The reclassified agreement rate is therefore a clinically relevant and pragmatic estimate for the accordance between large-core needle biopsy and actual disease status. This estimate, however, could only be calculated for two studies.
A DCIS underestimate rate of 15% indicates that 15% of the patients with a diagnosis of DCIS on large-core needle biopsy will prove to have invasive breast cancer at surgery. In most of these cases, an additional surgical procedure will then be necessary (axillary dissection with or without re-excision). Similarly, all patients with a diagnosis of ADH, atypical lobular hyperplasia, lobular carcinoma in situ or radial scar on large-core needle biopsy need to undergo open breast biopsy. Although the use of large-core needle biopsy eventually results in a correct histological diagnosis in these patient categories, large-core needle biopsy is an extra diagnostic procedure as compared to the situation with open breast biopsy as initial diagnostic procedure.
The pooled analysis showed a sensitivity rate of 97%. This value may be overestimated due to the non-blindness of the pathologists (Irwig et al, 1994) . In four studies large-core needle biopsy procedures as well as open biopsy procedures were performed on the same day (Parker et al, 1991; Elvecrog et al, 1993; Gisvold et al, 1994; Pijnappel et al, 1997) . Therefore, pathologists may not have been blinded for the results of the reference standard test (open biopsy).
Moreover, 56% of all lesions were derived from the study of Jackman et al (1999) . The relatively high sensitivity rate reported in this study has therefore substantially influenced the results of this meta-analysis.
Cut-off points for referral after breast cancer screening differ substantially between the USA and Europe. As a consequence, prevalence of malignancy among women referred for breast biopsy is approximately 20% in the USA compared to 60% in Europe. This difference can be explained by the fact that screening for breast cancer is more difficult in the USA than it is in Europe. In the first place, every American woman over 40 years is advised to undergo annual screening mammography, while in The Netherlands breast cancer screening starts at the age of 50. Because breast tissue is denser in younger women, screening mammograms will be more difficult to interpret, resulting in a lower sensitivity and specificity rate (Beemsterboer et al, 1998; UK Trial of Early Detection of Breast Cancer Group, 1999) . Secondly, in the USA, approximately 50% of post-menopausal women use hormone replacement therapy (HRT) (Grodstein et al, 1997) , compared to only 22% in the UK (Achuthan et al, 1999) . HRT influences the breast parenchyma, resulting in a decreased sensitivity and specificity rate of screening mammographies (Laya et al, 1996) . The difference in prevalence of malignancy leaves the practical consequences of replacing open biopsy by large-core needle biopsy open to discussion. In the USA, the need for minimally invasive and less expensive diagnostic tests is high because a large proportion of women undergoes benign breast biopsy. The risk of breast cancer in case of benign large-core core needle biopsy results is small (0.6%) in a population with relatively low breast cancer prevalence. On the contrary, in European screening settings the higher breast cancer prevalence among referred women will result in a relatively high risk of breast cancer in case of benign large-core needle biopsy (4-6%). One might argue which procedure is more effective in diagnosing breast cancer and preventing mortality of it: a rather unselective referral of women with low disease prevalence, worked up by the large-core needle procedure, or a more restricted selection of women with a relatively high disease prevalence, worked up by needle-localized open breast biopsy.
In addition, the miss rate of 3% may be reduced by identifying other high-risk categories, besides ADH, atypical lobular hyperplasia, lobular carcinoma in situ and radial scars. Perhaps the category of microcalcification lesions should be handled more cautiously, as it has been suggested that the miss rate of stereotactic large-core needle biopsy is higher for microcalcifications than for mass lesions (Burbank and Parker, 1998) .
In The Netherlands a prospective multicentre study (funded by the Ministry of Public Health) was started at the end of 1997 to address these issues. The study aims to include 1000 consecutive patients with non-palpable breast lesions who will all undergo both stereotactically guided large-core needle biopsy (14-gauge with a long-throw biopsy gun) on a prone table and surgical breast biopsy. Preferences of women and cost consequences will also be taken into account.
CONCLUSION
The high sensitivity rate (97%) and high reclassified agreement rate (94%) of the large-core needle biopsy make this technique a promising alternative for needle-localized open breast biopsy. However, additional research is required to elucidate limiting factors of the technique and to decide on optimal patient selection strategies. Without such detailed knowledge, a benign histological diagnosis on large-core needle biopsy in countries with high prevalence of malignancy among referred women should be handled with caution.
